Interactions with FDA over the past year have provided clear expectations for the path to submission of the nomlabofusp BLA Written FDA recommendations for safety database include a total of at least ...

Larimar Therapeutics, Inc. has announced a refined timeline for submitting a Biologics License Application (BLA) for its treatment nomlabofusp, aimed at addressing Friedreich's Ataxia (FA). Based on ...

The Vaccine Adverse Event Reporting System (VAERS) is a favorite tool of skeptics aiming to spread immunization fears. As it turns out, VAERS has actually helped ensure the safety of FDA-approved ...

The FDA has launched a free mobile app version of its Drugs@FDA online database that offers consumers information on agency-approved drugs. The new app, called Drugs@FDA Express, is free and currently ...

Entries include information on each product, their manufacturer and date of the agency's approval. New tobacco products that received marketing authorization through one of FDA's three pathways to ...

The FDA’s May 2021 draft guidance for post-approval studies for PMA devices did not present any regulatory novelties, but did propose tighter timelines for filing, reviewing and fulfilling ...

Please provide your email address to receive an email when new articles are posted on . Boston Scientific announced it received FDA approval for its drug-eluting stent system designed to treat large, ...

BALA CYNWYD, Pa., June 23, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare ...